Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake (angiogenesis)

This study has been completed.
Sponsor:
Collaborator:
J~pharma
Information provided by:
Gunma University
ClinicalTrials.gov Identifier:
NCT00671242
First received: April 30, 2008
Last updated: May 2, 2008
Last verified: January 2008
  Purpose

Purpose: L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC).

Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.


Condition
Angiogenesis
Non-Small Cell Lung Cancer

Study Type: Observational
Official Title: Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Gunma University:

Groups/Cohorts
I
L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
Nuclear

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who underwent a thoracotomy within 4 weeks after 18F-FMT PET and 18F-FDG PET study
  • Histology is non-small cell lung cancer

Exclusion Criteria:

  • Patient who received neoadjuvant chemotherapy or radiotherapy before surgery
  • Patients who have insulin-dependent diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00671242

Locations
Japan
Gunma University Graduate School of Medicine
showa-machi, Maebashi, Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
J~pharma
  More Information

No publications provided by Gunma University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00671242     History of Changes
Other Study ID Numbers: kkaira1970
Study First Received: April 30, 2008
Last Updated: May 2, 2008
Health Authority: Japan: Institutional Review Board

Keywords provided by Gunma University:
Fluorine-18-α-methyltyrosine,
Positron emission tomography,
Fluorine-18-fluorodeoxyglucose,
Lung cancer,
Angiogenesis
The median VEGF rate was 45% (range, 10-78%).
High expression was seen in 30 patients (81%, 30/37).
VEGF expression was statistically associated with progressively growing microvessel count.

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 20, 2014